Related Experiment Video
Updated: Sep 16, 2025
Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
Published on: February 4, 2021
DOCETAXEL-INDUCED PIGMENTARY MACULOPATHY
Henry C Skrehot1, Amer Alsoudi2, Emmanuel Y Chang3
1School of Medicine, Baylor College of Medicine, Houston, TX.
Purpose:
The objective of this study was to report a case of bilateral docetaxel-induced pigmentary maculopathy in an adult.
Methods:
A 79-year-old man with prostate cancer was treated with docetaxel and subsequently developed progressively worsening blurred vision. Before initiation of docetaxel therapy, his best corrected visual acuity was 20/20 in the right and left eye. He presented to clinic 5 months after the initiation of docetaxel therapy with best corrected visual acuity of 20/70 and 20/40 -2 in the right and left eye, respectively. Fundoscopic examination was notable for bilateral focal central areas of macular hyperpigmentation. Toxic maculopathy secondary to docetaxel was suspected, and the recommendation to discontinue docetaxel was made to the oncologist.
Results:
Five months after discontinuation of docetaxel, the patient's best corrected visual acuity improved to 20/40 -2 in the right and left eye. Fundoscopic examination was stable in both eyes.
Conclusion:
Bilateral pigmentary maculopathy presenting as focal areas of macular hyperpigmentation developed after the initiation of docetaxel in an adult with no previous ocular history. Prompt diagnosis and cessation of docetaxel resulted in stable disease.
More Related Videos
10:14Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration
Published on: May 26, 2023
09:24A Protocol to Evaluate and Quantify Retinal Pigmented Epithelium Pathologies in Mouse Models of Age-Related Macular Degeneration
Published on: March 10, 2023